An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD)
Phase of Trial: Phase III
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Nintedanib (Primary)
- Indications Interstitial lung diseases; Systemic scleroderma
- Focus Adverse reactions
- Acronyms SENSCIS (TM)-ON; SENSCIS(R) -ON
- Sponsors Boehringer Ingelheim
- 08 Dec 2017 Status changed from not yet recruiting to recruiting.
- 31 Oct 2017 Planned initiation date changed from 1 Nov 2017 to 27 Nov 2017.
- 24 Oct 2017 New trial record